Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica

Stemedica Cell Technologies has signed an agreement for its breakthrough stem cell and related technology. The Jordanian Stem Cell Company has signed a five year multi-million dollar agreement to purchase the technology from Stemedica’s wholly-owned subsidiary, Stemedica International.

Sam Alkhass, chief executive officer of Jordanian Stem Cell Company, said: We are delighted to be working with Stemedica International. Jordan has an excellent reputation as a provider of innovative and quality-driven medical treatment. It was fundamental to our company’s future, and Jordan’s reputation, that we find the best possible partner within the stem cell industry. We believe we have accomplished this objective by securing a long-term exclusive relationship with Stemedica International.

Nikolai Tankovich, president, and chief medical officer of Stemedica and vice chairman of Stemedica International, said: Stemedica International will be providing our state-of-the-art stem cell technology to the Jordanian Stem Cell Company and will actively support their development and implementation of a Clinical Trial for burns. We will work closely with the leadership of the Jordanian Stem Cell Company to secure all necessary governmental approvals for the Clinical Trial. The Trial is anticipated to begin sometime in the first quarter of 2010.